Tuesday, July 19, 2022

Tom’s #1 stock…

Cyber Trading University

Hi Friend,

Tom is hosting a special edition of his Wednesday on the Web session Wednesday @ 8pm ET.

He'll share the specific sectors he is looking at and his #1 stock going forward.

Plus one of the biggest announcements in DTI history…

Register Here

Happy Trading,
CTU Team

Unsubscribe | CyberTradingUniversity.com is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. In addition, owners, employees, or representatives of Cyber Trading University are not investment advisors or registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory. IMPORTANT NOTICE! No representation is being made that using this strategy or any trading methodology will be profitable. Past performance is not necessarily indicative of future results. There is substantial risk associated with equities trading of securities and options. Trading securities is not for everyone. Disclaimer: Day Trading, Swing trading, Stock Trading, Futures, Options, and Currency trading all have large potential rewards, but also large potential risk. You should be aware of the risks and accept them in order to invest in these markets. Do not trade with money you cannot afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures, options, or currencies. No representation or promise is being made that anyone is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading methodology is not necessarily a guarantee of future results. Visit our website below to read the full disclaimer. https://cybertradinguniversity.com/terms-of-use-disclosures/

Cyber Trading University
6800 Jericho Turnpike
Suite 116W
Syosset, New York 11791
United States
(877) 702-9237

No comments:

Post a Comment

Skirmish over paper drug info draws on

Delivered every Tuesday and Friday by 12 p.m., Prescription Pulse examines the latest pharmaceutical news and policy...